Canadian Scientists Report On Pain Research At NIDCR's 60th Anniversary Symposium Nearly everyone has experienced the acute, short-lived pain that occurs after a mild injury, but recent surveys reveal that more than 20% of the population has a chronic pain condition (i.e., pain that has lasted for 3 months or more) and for which treatment is often not very effective (e.g., low back pain, fibromyalgia, migraine headaches).
Source: www.medicalnewstoday.comPotential New Ways To Treat Metastatic Cancer Following Discovery Of Gene Mechanism Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming
healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.
Source: www.medicalnewstoday.comCrystalens HD? Receives FDA Approval Bausch & Lomb announced that it has received approval from the Food and Drug Administration (FDA) to market the Crystalens HD? in the United States. Crystalens accommodating intraocular lens (IOL) was first approved by the FDA in November 2003. The Crystalens HD is the fourth generation of the only FDA approved accommodating lens.
Source: www.medicalnewstoday.comInternational Meeting To Feature Knowledge Translation Symposium The mission of the International Association for Dental Research (IADR), convening here today for its 86th General Session, is to advance oral
health research worldwide, and to facilitate application of its findings. A special symposium will directly address the latter by drawing attention to methodologies that can ensure the improved uptake of research knowledge through Knowledge Translation.
Source: www.medicalnewstoday.comNanoViricides' Anti-EKC Drug Candidate To Be Studied In Japan NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that an internationally renowned Japanese ophthalmologist and corneal researcher, Kazuo Tsubota, MD, PhD, has agreed to perform confirmatory animal efficacy studies of the nanoviricide anti-EKC drug candidate, EKC-Cide?, against EKC (epidemic kerato-conjunctivitis) in Japan. Dr.
Source: www.medicalnewstoday.com
# posted by Network @ 6:02 AM
